- Home
- IPHA vs CADL Comparison
IPHA vs CADL Comparison
Compare IPHA & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- CADL
- Stock Information
- Founded
- IPHA 1999
- CADL 1999
- Country
- IPHA France
- CADL United States
- Employees
- IPHA N/A
- CADL N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- CADL Health Care
- Exchange
- IPHA Nasdaq
- CADL Nasdaq
- Market Cap
- IPHA 178.0M
- CADL 159.1M
- IPO Year
- IPHA 2019
- CADL 2021
- Fundamental
- Price
- IPHA $2.07
- CADL $8.75
- Analyst Decision
- IPHA Strong Buy
- CADL Strong Buy
- Analyst Count
- IPHA 1
- CADL 1
- Target Price
- IPHA $11.50
- CADL $19.00
- AVG Volume (30 Days)
- IPHA 1.5M
- CADL 9.7M
- Earning Date
- IPHA 09-12-2024
- CADL 11-14-2024
- Dividend Yield
- IPHA N/A
- CADL N/A
- EPS Growth
- IPHA N/A
- CADL N/A
- EPS
- IPHA N/A
- CADL N/A
- Revenue
- IPHA $36,202,722.00
- CADL N/A
- Revenue This Year
- IPHA N/A
- CADL N/A
- Revenue Next Year
- IPHA $102.87
- CADL N/A
- P/E Ratio
- IPHA N/A
- CADL N/A
- Revenue Growth
- IPHA N/A
- CADL N/A
- 52 Week Low
- IPHA $1.29
- CADL $1.08
- 52 Week High
- IPHA $3.51
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- IPHA 53.12
- CADL 68.05
- Support Level
- IPHA $1.47
- CADL $5.90
- Resistance Level
- IPHA $2.36
- CADL $7.28
- Average True Range (ATR)
- IPHA 0.32
- CADL 1.61
- MACD
- IPHA 0.06
- CADL 0.37
- Stochastic Oscillator
- IPHA 29.99
- CADL 55.04
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.